NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Mechanism of Action
2A -adrenergic receptor agonist. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.
Clinical Trials (5)
Drug Use Study With Intuniv® in Australia
Started Mar 2019
100 enrolled
Attention Deficit Hyperactivity Disorder (ADHD)
Drug Use Study With Intuniv® in European Countries
Started Nov 2018
5,000 enrolled
Attention Deficit Hyperactivity Disorder (ADHD)
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Started Mar 2012
215 enrolled
Attention Deficit Hyperactivity Disorder (ADHD)
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
Started Sep 2011
314 enrolled
Attention-Deficit/Hyperactivity Disorder
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Started Jan 2011
338 enrolled
Attention Deficit Hyperactivity Disorder